April 27, 2026
In an interview with Pharmacy Times at Asembia’s AXS26 Summit, Michael Oleksiw, CEO of Pleio addressed the challenge of medication nonadherence in specialty therapy, where nearly half of all treatment failures are tied to adherence issues. Mechanical interventions like push notifications alone fall short; overcoming nonadherence in specialty therapies requires AI-driven insights paired with human-centered outreach to tackle the emotional and psychological barriers patients face. Oleksiw highlighted GLP-1 medications as a prime example, where stigma, dose escalation, and recurring emotional hurdles make specialty therapy adherence especially difficult to sustain.
April 2, 2026
In part two of his Pharmaceutical Commerce interview series, Pleio CEO Michael Oleksiw reframes pharma’s adherence problem as fundamentally human — not logistical. From the industry’s persistent “one-and-done” challenge to the underestimated role of loneliness in early discontinuation, Oleksiw makes the case that lasting behavior change requires meeting patients emotionally before overwhelming them with tools, reminders, or information they aren’t yet ready to act on.
April 1, 2026
In his Pharma Live byline, Pleio CEO Michael Oleksiw puts empathetic AI to the test starting with a direct question to ChatGPT. The answer cuts to the heart of what the industry needs to hear: AI can simulate empathy, but it can’t feel it. In healthcare, where trust, emotional presence, and human judgment determine whether patients stay on therapy, that distinction isn’t semantic, it’s consequential.
April 1, 2026
In part one of his two-part Pharmaceutical Commerce interview series, Pleio CEO Michael Oleksiw unpacks the hidden barriers to adherence that legacy patient support programs were never built to detect — and makes the case that AI-powered insights are now giving pharma companies a clearer, faster window into why patients actually stop. With oral GLP-1 therapies reshaping the market, the cost of not knowing is growing.
March 31, 2026
Michael Oleksiw, CEO of Pleio, discusses the hidden gap in GLP-1 patient support programs and how to boost GLP-1 adherence.
March 31, 2026
Pleio’s Chief Experience Officer Abby Reynolds, PharmD, joined First Report Managed Care to discuss how emotional readiness shapes outcomes in specialty drug management — and why even clinically appropriate therapies stall when patients aren’t supported before functional demands peak.
FOR MEDIA INQUIRIES PLEASE EMAIL media@pleio.com.